← The Wire
NRIXNasdaq
Nurix Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1549595
Nurix Therapeutics discovers, develops, and commercializes targeted protein degradation medicines for cancer and inflammatory diseases
🔥 High media attention
$1.75B
Market cap
$23.85
Last close
+4.2%
1D
+27.9%
5D
2.7M
Volume
Price · last 39 sessions+40.9%
May 4L $14.64 · H $23.85Jun 29
143
Total filings
Jun 11, 2026
Last filing
11/30
Fiscal year end
10-K10-KJan 28, 202610-K10-KJan 28, 202510-K10-KFeb 15, 202410-K10-KFeb 9, 202310-K10-KJan 28, 202210-K10-KFeb 16, 2021
Insider Activity
In the 90 days to Mar 2, 2026: 3 sold $715K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Ring ChristineChief Legal Officer | Sell | 8,148 | $15.44 | $126K |
| Feb 9, 2026 | Ring ChristineChief Legal Officer | Sell | 14,261 | $16.66 | $238K |
| Jan 30, 2026 | Hansen GwennChief Scientific Officer | Sell | 4,797 | $16.58 | $80K |
| Jan 30, 2026 | Ring ChristineChief Legal Officer | Sell | 4,333 | $16.58 | $72K |
| Jan 30, 2026 | Van Houte HansChief Financial Officer | Sell | 3,588 | $16.58 | $59K |
| Jan 30, 2026 | Hansen GwennChief Scientific Officer | Sell | 98 | $17.37 | $2K |
| Jan 30, 2026 | Ring ChristineChief Legal Officer | Sell | 88 | $17.37 | $2K |
| Jan 30, 2026 | Van Houte HansChief Financial Officer | Sell | 73 | $17.37 | $1K |
| Jan 20, 2026 | Ring ChristineChief Legal Officer | Sell | 3,760 | $18.42 | $69K |
| Dec 18, 2025 | Ring ChristineChief Legal Officer | Sell | 3,560 | $17.87 | $64K |
| Dec 18, 2025 | Ring ChristineChief Legal Officer | Sell | 200 | $18.56 | $4K |
| Nov 24, 2025 | Ring ChristineChief Legal Officer | Sell | 37,600 | $17.07 | $642K |
| Nov 3, 2025 | Van Houte HansChief Financial Officer | Sell | 6,284 | $12.56 | $79K |
| Oct 30, 2025 | Hansen GwennChief Scientific Officer | Sell | 4,087 | $12.80 | $52K |
| Oct 30, 2025 | Ring ChristineChief Legal Officer | Sell | 3,644 | $12.80 | $47K |
| Oct 30, 2025 | Van Houte HansChief Financial Officer | Sell | 3,130 | $12.80 | $40K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 4 reputable articles · skews ▲ positive.
Investor's Business DailyRoche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying21d agoBarron'sThis Biotech Stock Is Popping 10% on $2.3 Billion Roche Deal for Blood Cancer Drug21d agoReutersRoche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics22d agoWSJRoche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion22d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance